Corpus Intelligence IC Memo — AIKEN REGIONAL MEDICAL CENTER 2026-04-26 03:50 UTC
IC Memo — AIKEN REGIONAL MEDICAL CENTER
Investment Committee Memorandum | SC | 211 beds | Grade C | EBITDA uplift $14.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

AIKEN REGIONAL MEDICAL CENTER

CCN 420082 | AIKEN, SC | 211 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

AIKEN REGIONAL MEDICAL CENTER is a 211-bed suburban community hospital in AIKEN, SC with $202.3M in net patient revenue and a -0.0% operating margin. The hospital serves a payer mix of 26.7% Medicare, 8.6% Medicaid, and 64.7% commercial.

Thesis: Undervalued. Our ML models identify $14.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.0% to 7.3% (+736bps).

Net Revenue HCRIS$202.3M
Current EBITDA COMPUTED$-48K
Operating Margin COMPUTED-0.0%
Occupancy HCRIS64.0%
Revenue / Bed COMPUTED$959K
Net-to-Gross HCRIS13.6%
Distress Probability ML44.9%

2. Market Context & Competitive Position

85
SC Hospitals
1.3%
State Median Margin
26
Comparable Hospitals

SC has 85 Medicare-certified hospitals with a median operating margin of 1.3%. The target's margin of -0.0% places it below the state median. Among 26 size-comparable peers (106-422 beds), the median margin is 2.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (106-422), prioritizing same-state peers. 26 hospitals in the comp set.

HospitalStateBedsRevenueMargin
AIKEN REGIONAL MEDICAL CENTER (Target)SC211$202.3M-0.0%
ST. FRANCIS HOSPITAL INCSC327$691.4M4.9%
TRIDENT REGIONAL MEDICAL CENTESC388$637.5M16.1%
GRAND STRAND REGIONAL MEDICAL SC336$602.2M32.8%
ANMED HEALTHSC367$596.7M-2.3%
SELF REGIONAL HEALTHCARESC290$410.1M4.7%
ROPER HOSPITAL INC.SC266$400.8M-3.0%
PIEDMONT MEDICAL CENTERSC374$387.0M8.3%
BON SECOURS ST. FRANCIS XAVIERSC186$304.6M12.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $14.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.2M+210bp18mo
Cost to Collect4.5%2.5%$4.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.5M+122bp9mo
Clean Claim Rate88.0%96.0%$129K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.2M
Cost to Collect
$4.0M
Denial Rate Reduction
$4.0M
A/R Days Reduction
$2.5M
Clean Claim Rate
$129K
Total EBITDA Uplift$14.9M
Current EBITDA$-48K
+ RCM Uplift+$14.9M
Pro Forma EBITDA$14.8M
Current Margin-0.0%
Pro Forma Margin7.3%
WC Released (1x)$7.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-73K$148.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-73K$163.4M0.00x-100.0%
Bull Case9.0x11.0x$-66K$212.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-66K$231.8M0.00x-100.0%
Bear Case11.0x10.0x$-81K$74.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-81K$81.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 26 hospitals with 106-422 beds
  • Same-state prioritization (n=27)
  • Comp margins: P25=-7.0% / P50=2.7% / P75=10.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.